Ultralow Risk 70-Gene Promises Superior Survival Outcomes in Patients with Early-Stage Breast Cancer
Oncology Nursing News,
The phase 3 MINDACT trial (NCT00433589) demonstrated that patients with early-stage breast cancer who have ultralow risk…
The phase 3 MINDACT trial (NCT00433589) demonstrated that patients with early-stage breast cancer who have ultralow risk…
A 70-gene signature indicated women with early-stage breast cancer who have ultralow risk disease and would demonstrate an…
At a median follow-up of 8.7 years, the 8-year distant metastasis-free interval (DMFI) rate in patients with ultralow-risk…